Why the PD-L1-high subgroup could be crucial for Summit Therapeutics’ global strategy
Summit shares rise after ivonescimab delivers 30.8-month survival versus 22.6 months for pembrolizumab in China’s HARMONi-2 trial.
Pharma & Biotech
Pharma & Biotech
Lancet Oncology publishes Summit’s global ivonescimab Phase 3 with PFS at 6.8 months versus 4.4
Global HARMONi data show ivonescimab plus chemotherapy reduced progression or death risk by 48% after third-generation EGFR-TKI failure, while overall survival had not reached statistical significance at the primary analysis.
Pharma & Biotech
Akeso adds B7-H3 to its ADC strategy, but AK157D1 enters a field where a rival is already under FDA review
China has cleared Akeso’s AK157D1 for Phase 1 testing in advanced solid tumors, adding a DXd-class B7-H3 programme to a target already attracting late-stage ADC competition.
Pharma & Biotech
Akeso is betting a dual-target ADC can break through breast cancer’s increasingly crowded treatment field
Akeso starts Phase II testing of AK146D1 plus ivonescimab in advanced breast cancer. See what the dual-target ADC strategy must prove.
Pharma & Biotech
What Akeso’s AK138D1 and ivonescimab combination must prove in advanced NSCLC
Akeso has started a Phase Ib/II lung cancer trial of HER3 ADC AK138D1 with ivonescimab. See what the combination must prove.
Pharma & Biotech
Summit Therapeutics has $690.7m, but one November FDA decision now towers over everything
Summit Therapeutics ends Q2 with $690.7m as ivonescimab approaches an FDA decision and pivotal HARMONi-3 data in late 2026.
Pharma & Biotech
Summit Therapeutics nears FDA decision with stronger ivonescimab survival signal
Ivonescimab’s updated HARMONi survival trend strengthens before the FDA’s November decision, but key statistical details remain undisclosed.
Pharma & Biotech
Can Summit and Akeso turn ivonescimab into a global lung cancer challenger?
Ivonescimab showed an overall survival benefit in HARMONi-6. Read how the data could reshape first-line squamous NSCLC treatment.
Pharma & Biotech
Can Akeso’s ivonescimab ASCO plenary data reset expectations in lung cancer?
Akeso’s ivonescimab faces a defining ASCO test as lung cancer rivals watch whether PD-1/VEGF bispecifics can scale globally.
Pharma & Biotech
Ivonescimab delivers 80% response in TNBC: Is Akeso redefining PD-1 treatment?
Ivonescimab shows 80 percent response in TNBC Phase II study. Explore how Akeso’s bispecific strategy could reshape PD-1 therapy in first-line settings.